Blueprint Medicines will receive $25 million to collaborate with the French drug maker Ipsen on a potential medical treatment that the Cambridge, Mass., biotech has developed for an ultra-rare genetic disease.
The licensing deal marks the fourth collaboration between Blueprint — founded in 2008 — and another major drug maker in less than five years.
